S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
NASDAQ:ADAP

Adaptimmune Therapeutics (ADAP) Stock Price, News & Analysis

$1.58
+0.06 (+3.95%)
(As of 03/27/2024 ET)
Today's Range
$1.47
$1.63
50-Day Range
$0.70
$1.75
52-Week Range
$0.42
$2.05
Volume
1.18 million shs
Average Volume
2.03 million shs
Market Capitalization
$1.57 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00

Adaptimmune Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
216.5% Upside
$5.00 Price Target
Short Interest
Healthy
0.31% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.36mentions of Adaptimmune Therapeutics in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$30,693 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.44) to ($0.41) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.76 out of 5 stars

Medical Sector

650th out of 939 stocks

Biological Products, Except Diagnostic Industry

113th out of 156 stocks

ADAP stock logo

About Adaptimmune Therapeutics Stock (NASDAQ:ADAP)

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

ADAP Stock Price History

ADAP Stock News Headlines

Adaptimmune Therapeutics (NASDAQ:ADAP) Trading Up 4.5%
Altcoin FRENZY Alert…
Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days…
Adaptimmune Therapeutics (NASDAQ:ADAP) Shares Gap Up to $1.41
Peter W. Sonsini's Net Worth
ADAP Sep 2024 2.500 put
Major Elon Musk Crypto Leak Revealed
Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.
Adaptimmune Therapeutics Earnings Preview
Adaptimmune Therapeutics earnings: here's what Wall Street expects
ADAP Apr 2024 1.500 put
ADAP Apr 2024 2.000 call
Adaptimmune Therapeutics PLC ADR
ADAP Sep 2024 2.000 call
ADAP Jun 2024 1.000 call
See More Headlines
Receive ADAP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adaptimmune Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/04/2021
Today
3/28/2024
Next Earnings (Estimated)
5/10/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:ADAP
Employees
449
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.00
High Stock Price Target
$10.00
Low Stock Price Target
$1.00
Potential Upside/Downside
+216.5%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

Net Income
$-113,870,000.00
Net Margins
-188.90%
Pretax Margin
-186.68%

Debt

Sales & Book Value

Annual Sales
$60.28 million
Book Value
$0.04 per share

Miscellaneous

Free Float
821,518,000
Market Cap
$1.57 billion
Optionable
Optionable
Beta
2.40
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives


ADAP Stock Analysis - Frequently Asked Questions

Should I buy or sell Adaptimmune Therapeutics stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Adaptimmune Therapeutics in the last year. There are currently 1 sell rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ADAP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ADAP, but not buy additional shares or sell existing shares.
View ADAP analyst ratings
or view top-rated stocks.

What is Adaptimmune Therapeutics' stock price target for 2024?

2 Wall Street analysts have issued 12-month target prices for Adaptimmune Therapeutics' shares. Their ADAP share price targets range from $1.00 to $10.00. On average, they predict the company's stock price to reach $5.00 in the next year. This suggests a possible upside of 216.5% from the stock's current price.
View analysts price targets for ADAP
or view top-rated stocks among Wall Street analysts.

How have ADAP shares performed in 2024?

Adaptimmune Therapeutics' stock was trading at $0.7930 at the start of the year. Since then, ADAP stock has increased by 99.2% and is now trading at $1.58.
View the best growth stocks for 2024 here
.

Are investors shorting Adaptimmune Therapeutics?

Adaptimmune Therapeutics saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 3,110,000 shares, an increase of 11.1% from the February 29th total of 2,800,000 shares. Based on an average daily volume of 1,850,000 shares, the short-interest ratio is currently 1.7 days.
View Adaptimmune Therapeutics' Short Interest
.

When is Adaptimmune Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our ADAP earnings forecast
.

How were Adaptimmune Therapeutics' earnings last quarter?

Adaptimmune Therapeutics plc (NASDAQ:ADAP) announced its quarterly earnings results on Thursday, November, 4th. The biotechnology company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.26) by $0.04. The biotechnology company earned $1.20 million during the quarter, compared to the consensus estimate of $1.20 million. Adaptimmune Therapeutics had a negative trailing twelve-month return on equity of 155.39% and a negative net margin of 188.90%. During the same quarter in the prior year, the company earned ($0.23) EPS.

What ETF holds Adaptimmune Therapeutics' stock?

Simplify Propel Opportunities ETF holds 150,000 shares of ADAP stock, representing 0.13% of its portfolio.

What is Adrian Rawcliffe's approval rating as Adaptimmune Therapeutics' CEO?

6 employees have rated Adaptimmune Therapeutics Chief Executive Officer Adrian Rawcliffe on Glassdoor.com. Adrian Rawcliffe has an approval rating of 100% among the company's employees. This puts Adrian Rawcliffe in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Adaptimmune Therapeutics own?
When did Adaptimmune Therapeutics IPO?

Adaptimmune Therapeutics (ADAP) raised $150 million in an initial public offering (IPO) on Wednesday, May 6th 2015. The company issued 9,400,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch, Cowen and Company and Leerink Partners served as the underwriters for the IPO and Guggenheim Securities was co-manager.

Who are Adaptimmune Therapeutics' major shareholders?

Adaptimmune Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (1.60%), Citadel Advisors LLC (0.34%), GSA Capital Partners LLP (0.05%), Key Client Fiduciary Advisors LLC (0.03%), Harbor Capital Advisors Inc. (0.01%) and Twin Focus Capital Partners LLC (0.01%). Insiders that own company stock include Adrian Rawcliffe, Cintia Piccina, Elliot Norry, Garry E Menzel, Gavin Wood, John Lunger and William C Bertrand Jr.
View institutional ownership trends
.

How do I buy shares of Adaptimmune Therapeutics?

Shares of ADAP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ADAP) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners